title: Serial lung function testing in patients treated with amiodarone: a prospective study.
abstract: OBJECTIVE
  Amiodarone has proven to be effective in many cases of cardiac arrhythmias, refractory ventricular tachycardia, and ventricular fibrillation. Pulmonary toxicity is a possible side effect of the drug, with a reported incidence of 2 to 15 percent per year. To determine the effect of amiodarone on lung function, we prospectively studied serial lung function tests in a cohort of 91 patients with refractory cardiac arrhythmias treated with this agent.
  
  
  METHODS
  Spirometry and carbon monoxide diffusing capacity (DLCO) were measured at zero, three, six, 12, 18, and 24 months, with a mean follow-up of 351 days.
  
  
  RESULTS
  For the whole population taking a mean dose of amiodarone of 367 mg daily (range: 136 to 512 mg), there was no accelerated rate of decline in spirometric indices or DLCO. Analysis of lung function changes by multivariate analysis demonstrated that an accelerated decline in DLCO values occurred in elderly patients (p less than 0.05) but not in patients with pre-existing lung disease or cigarette smokers. In four patients (4.5 percent), clinical evidence of amiodarone pulmonary toxicity developed that was associated with a fall in DLCO of greater than 20 percent. All four patients recovered after the drug was stopped. Another 15 patients, without clinical evidence of pulmonary toxicity, had a sustained decline in DLCO of greater than 20 percent. These 15 patients remained asymptomatic over the next 11 months without interruption of therapy. A greater than 20 percent fall in DLCO was a sensitive test for clinically evident amiodarone pulmonary toxicity, but had a positive predictive value of only 21 percent.
  
  
  CONCLUSIONS
  An isolated fall in DLCO, in the absence of clinical evidence of toxicity, does not necessitate stopping amiodarone. An unchanged DLCO value appears to be a reliable negative predictor of pulmonary toxicity.
authors.affiliation: Johns Hopkins Hospital, Baltimore, Maryland.
authors.forename: I C
authors.initials: IC
authors.lastname: Gleadhill
authors.forename: R A
authors.initials: RA
authors.lastname: Wise
authors.forename: S A
authors.initials: SA
authors.lastname: Schonfeld
authors.forename: P P
authors.initials: PP
authors.lastname: Scott
authors.forename: T
authors.initials: T
authors.lastname: Guarnieri
authors.forename: J H
authors.initials: JH
authors.lastname: Levine
authors.forename: L S
authors.initials: LS
authors.lastname: Griffith
authors.forename: E P
authors.initials: EP
authors.lastname: Veltri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000009:adverse effects*; D002248:Carbon Monoxide / Q000378:metabolism; D004058:Diffusion; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D013147:Spirometry; D014797:Vital Capacity
chemical_list: D002248:Carbon Monoxide; D000638:Amiodarone